Neurotech Pharmaceuticals, Inc.

Neurotech Pharmaceuticals, Inc. is a private, clinical-stage biotechnology company headquartered at 900 Highland Corporate Drive, Suite 101, in Cumberland, Rhode Island, with a commercial office at 75 Second Ave, Suite 700, in Needham, Massachusetts. The company describes itself as focused on developing transformative therapies for chronic eye diseases, and its work centers on the retina. Its lead therapeutic area is Macular Telangiectasia Type 2 (MacTel), a bilateral retinal disease that causes gradual loss of central vision as photoreceptors are lost in a well-defined area of the retina known as the Ellipsoid Zone. Patients with MacTel experience blurring, distorted vision, difficulty reading, and loss of central vision. Neurotech's core technology is its Encapsulated Cell Therapy (ECT) Platform, which releases Ciliary Neurotrophic Factor (CNTF), a protein shown to protect against the progressive loss of photoreceptors. The company states that there are no known pharmacological treatment options for MacTel today, positioning its platform as a potential first-in-class approach. Its product ENCELTO (revakinagene taroretcel-lwey) has received FDA approval, and the company reported that the first FDA-approved treatment for MacTel was performed in August 2025. Neurotech also announced that it was granted a permanent J-Code (J3403) for ENCELTO effective October 1, 2025. The company is led by a leadership team and governed by a board of directors, with a medical advisory board that includes retinal specialists such as María H. Berrocal, MD; Barbara Blodi, MD; Allen C. Ho, MD; Dean Eliott, MD; Anne E. Fung, MD; Dante Pieramici, MD; and Charles C. Wykoff, MD PhD. Peter J. McDonnell, M.D., was appointed to the company's board of directors in September 2025, and Beth Marsh was appointed Chief Commercial Officer in April 2025. Neurotech maintains a presence on LinkedIn, Twitter, and Instagram and lists a main phone number of 401-333-3880. As a private company, it does not trade on a public stock exchange.

Neurotech Pharmaceuticals, Inc. is a private biotech company based in Cumberland, Rhode Island, focused on developing transformative therapies for chronic eye diseases. The company's scientific foundation rests on its Encapsulated Cell Therapy (ECT) Platform, which is designed to release Ciliary Neurotrophic Factor (CNTF), a protein shown to protect against the progressive loss of photoreceptors. This platform underpins the company's therapeutic programs in retinal disease. The company's lead therapeutic focus is Macular Telangiectasia Type 2 (MacTel), a bilateral retinal disease that leads to a gradual loss of central vision. In MacTel, photoreceptors are lost in a well-defined area of the retina known as the Ellipsoid Zone, and as the disease progresses, patients experience blurring, distorted vision, trouble reading, and loss of central vision. Neurotech notes that there are no known pharmacological treatment options for MacTel today, which frames its development efforts as addressing a significant unmet need. Neurotech's product ENCELTO (revakinagene taroretcel-lwey) received FDA approval, and on August 11, 2025, the company announced that the first FDA-approved treatment for MacTel had been performed. On September 29, 2025, Neurotech announced that it had been granted a permanent J-Code (J3403) for ENCELTO, effective October 1, 2025. These developments mark the company's transition from a clinical-stage organization toward commercial operations. In support of that transition, Neurotech appointed Beth Marsh as Chief Commercial Officer on April 21, 2025. On September 2, 2025, Peter J. McDonnell, M.D., was appointed to the company's board of directors. The company also provides corporate updates on its commercial progress, including one dated March 12, 2026. Neurotech maintains a leadership team, a board of directors, and a medical advisory board composed of retinal specialists. Its headquarters are located at 900 Highland Corporate Drive, Suite 101, Cumberland, RI 02864, and it operates a commercial office at 75 Second Ave, Suite 700, Needham, MA 02494.

• Beth Marsh appointed Chief Commercial Officer.

• First FDA-approved treatment for MacTel performed.

• Peter J. McDonnell, M.D., appointed to the Board of Directors.

• Permanent J-Code (J3403) granted for ENCELTO, effective October 1, 2025.

• Corporate update on commercial progress provided.

Private clinical-stage biotech developing transformative therapies for chronic eye diseases, with a focus on retinal diseases such as Macular Telangiectasia Type 2.

• ENCELTO (revakinagene taroretcel-lwey)

  FDA-approved encapsulated cell therapy for Macular Telangiectasia Type 2.

• Encapsulated Cell Therapy (ECT) Platform

  Platform that releases Ciliary Neurotrophic Factor (CNTF) to protect against progressive loss of photoreceptors.

• 2026-10-20

  Alcon acquires Neurotech Pharmaceuticals[6]Alcon 收购 Neurotech Pharmaceuticalsfinanznachrichten.de

  Reported: 2026-10-20

  Alcon announced that it had acquired Neurotech Pharmaceuticals for $550 million, with possible additional contingent payments tied to commercial milestones.

1. 1Encapsulated Cell Therapy | Neurotech Pharmaceuticals, Inc. | Cumberlandneurotechpharmaceuticals.com
2. 2Macular Telangiectasia | About Neurotech Pharmaceuticalsneurotechpharmaceuticals.com
3. 3Meet the Team | Neurotech Pharmaceuticals, Inc Cumberland, RIneurotechpharmaceuticals.com
4. 4Medical Advisory Board | neurotechneurotechpharmaceuticals.com
5. 5Neurotech (United States)wikidata.org
6. 6Alcon 收购 Neurotech Pharmaceuticalsfinanznachrichten.de
7. 7Alcon Acquires Neurotech Pharmaceuticals for $550M - Orange County Business Journalocbj.com